Volume 2.28 | Jul 18

Pulmonary Cell News 2.28 July 18, 2013
Pulmonary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pulmonary Cell News on Twitter
 
TOP STORY
miR-205 Targets PTEN and PHLPP2 to Augment AKT Signaling and Drive Malignant Phenotypes in Non-Small Cell Lung Cancer
Scientists report upregulation of the oncomir miR-205 in multiple subtypes of non-small cell lung cancer (NSCLC), which directly represses PTEN and PHLPP2 expression and activates both the AKT/FOXO3a and AKT/mTOR signaling pathways. miR-205 overexpression in NSCLC cells accelerated tumor cell proliferation and promoted blood vessel formation in vitro and in vivo. [Cancer Res] Abstract
Model the Human Respiratory Epithelium with PneumaCult™-ALI. Click to View Data.
 
PUBLICATIONS (Ranked by impact factor of the journal)
ErbB4 Is an Upstream Regulator of TTF-1 Fetal Mouse Lung Type II Cell Development In Vitro
Overexpression of ErbB4 and TTF-1 was analyzed in its effect on cell viability, surfactant protein (Sftp)b expression, TTF-1 expression, and Sftpb and TTF-1 promoter activity. ErbB4 ligand neuregulin induces ErbB4 and TTF-1 co-precipitation and nuclear colocalization. [Biochim Biophys Acta] Abstract

ATP Release and Ca2+ Signaling by Human Bronchial Epithelial Cells following Alternaria Aeroallergen Exposure
Pretreatment of human bronchial epithelial (HBE) with a cell permeable Ca2+ chelating compound (BAPTA-AM) significantly inhibited ATP release, indicating dependency on [Ca2+]i. Alternaria-evoked ATP release exhibited a greater peak response and a slightly lower EC50 value in cells obtained from asthmatic donors compared to normal control cells. [J Physiol] Abstract

Mitochondrial Proteomic Analysis of Human Host Cells Infected with H3N2 Swine Influenza Virus
Researchers analyzed the differential mitochondrial proteomes of H3N2 SIV-infected human lung A549 cells using two-dimensional gel electrophoresis followed by matrix-assisted laser desorption ionization time-of-flight/time-of-flight analysis. In the comparative analysis, 24 altered proteins were identified in the mitochondria of H3N2 SIV-infected cells; these proteins were involved in cell-to-cell signaling and interaction, cellular movement, and post-translational modification. [J Proteomics] Abstract

Large Uptake of Titania and Iron Oxide Nanoparticles in the Nucleus of Lung Epithelial Cells as Measured by Raman Imaging and Multivariate Classification
Raman imaging, a label-free technique that requires no extensive sample preparation, was combined with multivariate classification to quantify the spatial distribution of oxide nanoparticles inside living lung epithelial cells. Using multivariate classification of hyperspectral Raman data with partial least-squares discriminant analysis, scientists showed that a surprisingly large fraction of spectra, classified as belonging to the cell nucleus, show Raman bands associated with nanoparticles. [Biophys J] Abstract

The Role of Asbestos Morphology on Their Cellular Toxicity: An In Vitro 3D Raman/Rayleigh Imaging Study
Scientists developed a 3D Raman/optical imaging methodology in vitro to characterize both morphological and chemical parameters of cell/fiber interactions. They determined that lung cells could vesiculate amphiboles with length below 5 µm or could embed those not exceeding 15 µm in their fibrous extracellular matrix. [Anal Bioanal Chem] Abstract

LUNG CANCER

Airway Basal Cells of Healthy Smokers Express an Embryonic Stem Cell Signature Relevant to Lung Cancer
Scientists found that the human embryonic stem cell (hESC) signature is selectively induced in the airway basal stem/progenitor cell population of healthy smokers (BC-S), with a pattern similar to that activated in all major types of human lung cancer. They further identified a subset of 6 BC-S hESC genes, whose coherent overexpression in lung AdCa was associated with reduced lung function, poorer differentiation grade, more advanced tumor stage, remarkably shorter survival and higher frequency of TP53 mutations. [Stem Cells] Abstract

Dioxin and Estrogen Signaling in Lung Adenocarcinoma Cells with Different AhR/ERa Phenotypes
Scientists examined dioxin and estrogen signaling crosstalk in lung adenocarcinoma cell lines that were engineered to exhibit different AhR/ERa phenotypes. Data showed that 2,3,7,8-tetrachlorodibenzo-p-dioxin weakly antagonized estrogen-activated ERa activity in cells expressing abundant ERa but little AhR. [Am J Respir Cell Mol Biol] Abstract

Expression and Clinical Role of Small Glutamine-Rich Tetratricopeptide Repeat (TPR)-Containing Protein Alpha (SGTA) as a Novel Cell Cycle Protein in NSCLC
Researchers determined whether SGTA could serve as a biomarker for stratification and prediction of prognosis in non-small-cell lung cancer (NSCLC). They demonstrated that suppression of SGTA expression resulted in a significant decline of proliferation in A549 cells. [J Cancer Res Clin Oncol] Abstract

Expression and Significance of miRNA-21 and BTG2 in Lung Cancer
Scientists examined the impact of micro-ribonucleic acid-21 (miRNA-21) on biological characteristics of lung cancer cells, such as growth, proliferation, apoptosis, and invasion. miRNA-21 expression was significantly higher in lung cancer cell lines than that in normal human bronchial epithelial cells. The pattern of B cell translocation gene 2 (BTG2) protein expression was exactly the opposite of miRNA-21 expression in lung cancer cells. [Tumor Biol] Abstract

View On-Demand Webinar: Optimized Differentiation of Bronchial Epithelial Cells
 
REVIEWS
The Impact of Genomic Changes on Treatment of Lung Cancer
The authors summarize oncogenic drivers in non-small cell lung cancer that can be currently detected, highlight their potential therapeutic implications, and discuss practical considerations for successful application of tumor genotyping in clinical decision-making. [Am J Respir Crit Care Med] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
 
INDUSTRY NEWS
U.S. FDA Approves Gilotrif™ (Afatinib) as First-Line Treatment for Lung Cancer Patients with EGFR Mutations
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved afatinib tablets under the U.S. brand name GILOTRIFTM for oral use, as a new first-line treatment for patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 substitution mutations as detected by an FDA-approved test. [Boehringer Ingelheim GmbH] Press Release

QIAGEN Receives FDA Approval for Therascreen® EGFR RGQ PCR Kit as a Companion Diagnostic for Lung Cancer Patients
QIAGEN N.V. announced it has received approval by the U.S. Food and Drug Administration (FDA) to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim’s new targeted therapy, GILOTRIFTM (afatinib), for treatment of metastatic NSCLC in patients whose tumors have certain EGFR gene mutations. [QIAGEN N.V.] Press Release

The European Cancer Congress 2013
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

From our sponsor:
Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
 
EVENTS
NEW 18th Congress Of The Asia Pacific Society Of Respirology 2013 (APSR 2013)
November 11-14, 2013
Yokohama, Japan

Visit our events page to see a complete list of events in the pulmonary cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Research Scientist – Asthma (Columbia University)

Principal Investigator – Oncology/Respiratory Medicine (The Second Affiliated Hospital of Zhejiang University School of Medicine)

Postdoctoral Fellow – ERK3 Kinase Signaling in Cancer Progression and Metastasis (Wright State University)

Postdoctoral Researcher – Molecular Determinants of Resistance to Chemotherapy and Radiation (The Ohio State University – Comprehensive Cancer Center)

Postdoctoral Fellow – Translational Oncology (The University of Texas MD Anderson Cancer Center)

Director of Cell Processing Facility (S L Collins Associates, Inc.)

PhD Opportunity – Biofunctionalization of Liposomes for Tumor-Targeted Drug Delivery (University of East Anglia)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Pulmonary Cell News: Archives | Events | Contact Us